307 related articles for article (PubMed ID: 17979896)
1. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
Garber AJ; Clauson P; Pedersen CB; Kølendorf K
J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
[TBL] [Abstract][Full Text] [Related]
2. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
Bartley PC; Bogoev M; Larsen J; Philotheou A
Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
[TBL] [Abstract][Full Text] [Related]
6. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.
Davies MJ; Derezinski T; Pedersen CB; Clauson P
Diabetes Technol Ther; 2008 Aug; 10(4):273-7. PubMed ID: 18715200
[TBL] [Abstract][Full Text] [Related]
7. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
8. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
[TBL] [Abstract][Full Text] [Related]
9. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
10. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
[TBL] [Abstract][Full Text] [Related]
11. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Fritsche A; Schweitzer MA; Häring HU;
Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
[TBL] [Abstract][Full Text] [Related]
12. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
13. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Hermansen K; Davies M; Derezinski T; Martinez Ravn G; Clauson P; Home P
Diabetes Care; 2006 Jun; 29(6):1269-74. PubMed ID: 16732007
[TBL] [Abstract][Full Text] [Related]
14. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
Sreenan S; Virkamäki A; Zhang K; Hansen JB;
Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
[TBL] [Abstract][Full Text] [Related]
15. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
[TBL] [Abstract][Full Text] [Related]
16. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
Kølendorf K; Ross GP; Pavlic-Renar I; Perriello G; Philotheou A; Jendle J; Gall MA; Heller SR
Diabet Med; 2006 Jul; 23(7):729-35. PubMed ID: 16842476
[TBL] [Abstract][Full Text] [Related]
17. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
Frier BM; Russell-Jones D; Heise T
Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900
[TBL] [Abstract][Full Text] [Related]
18. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
Standl E; Lang H; Roberts A
Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
[TBL] [Abstract][Full Text] [Related]
19. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
[TBL] [Abstract][Full Text] [Related]
20. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
Oishi M; Abe N; Yokoyama H; Kuribayashi N; Tomonaga O; Matoba K; Kobayashi M;
J Int Med Res; 2012; 40(2):787-97. PubMed ID: 22613444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
